Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • emolinari
    Member
    • May 2013
    • 47

    #1

    Low mapping TopHat

    Hi guys,

    another problem to solve. I am running TopHat on some human cells samples I have submitted to our facility for RNAseq. The bioanalyzer values were great (all above RIN 8.5) and thus a library based exclusively on ribo depletion has been created.
    I have multiplexed 4 samples in a lane (75bp, single-end) and obtained roughly 50 mil reads for each sample.
    This is my TopHat summary:

    Reads kept by tophat2 for mapping: 48777778
    Reads discarded by tophat2: 321249

    Number of unique reads that mapped: 5922988
    Percentage of unique reads that mapped: 12.06%

    I have used transcriptome for Tophat2...but I cannot understand why such a low mapping percentage (not the same across the samples, ranges across 12-40%).
    Do you have any idea???
    Other groups in our lab (doing polyA selection, on same cells, using same RNAseq pipeline) map almost 90% of the reads.

    Help me please!!!
    Thanks
    Manu
  • kopi-o
    Senior Member
    • Feb 2008
    • 319

    #2
    Perhaps a lot of rRNA left in the samples, leading to many multimapping reads due to repetitiveness, or "duplicates" which are really rRNA genes with very high coverage. It could also be adapter contamination but I have seen such low mapping rates often in e g RiboMinus samples due to poor rRNA removal.

    Comment

    • sdriscoll
      I like code
      • Sep 2009
      • 436

      #3
      It might be useful to grab some random read sequences that didn't align (tophat makes a file called unmapped.bam) and try aligning them with BLAST and see what it comes up with. not very efficient but if you repeatedly see poor / no alignments from BLAST you can be pretty sure that Tophat isn't messing up.

      You can pull some reads from it like this:

      Code:
      samtools view unmapped.bam | \
        perl -slane 'if(rand() < 0.000001) { print ">$F[0]\n$F[9]"; }' > random_reads.fa
      You can tweak that value in the if test to control how much gets extracted. What I did here should pull on average 1 read per million.
      /* Shawn Driscoll, Gene Expression Laboratory, Pfaff
      Salk Institute for Biological Studies, La Jolla, CA, USA */

      Comment

      • emolinari
        Member
        • May 2013
        • 47

        #4
        Thanks for both suggestions!
        I have run the script and I BLASTed the unmapped reads of one of my samples...
        apparently most of my reads match with a pre-rRNA (or rRNA in general) and also incredibly to some exotic fish, which I assume is a mere coincidence and an artifact.
        So my question is: shouldn't rRNA map anyhow to the transcriptome?
        More: is there any strategy to limit such a huge contamination? (I really need to do ribo depletion rather than polyA selection)

        Thanks a lot!!!
        Manu

        Comment

        • Gonza
          Member
          • Mar 2013
          • 78

          #5
          Hi,

          I have a quick follow up question......I am using that perl script to see why i am getting sooo low % of mapped reads (60%). When i run it i only pull ~ 11 samples of ~ 120 bp (not really a million reads). Am i missing something?

          Comment

          • GenoMax
            Senior Member
            • Feb 2008
            • 7142

            #6
            Originally posted by Gonza View Post
            Hi,

            I have a quick follow up question......I am using that perl script to see why i am getting sooo low % of mapped reads (60%). When i run it i only pull ~ 11 samples of ~ 120 bp (not really a million reads). Am i missing something?
            @sdriscoll's code pulls one read from a million sampled so you must have about 11 million reads that are in unmapped.bam. You can change the "0.000001" value to sample more reads.

            While it is possible that your samples are contaminated with something (either because of something you did or the sequencing facility did) you will want to take a more careful look before concluding anything.

            Brian asked a set of questions in your other post so let us see what you have to say about those.

            Comment

            Latest Articles

            Collapse

            • SEQadmin2
              Beyond CRISPR/Cas9: Understand, Choose, and Use the Right Genome Editing Tool
              by SEQadmin2



              CRISPR/Cas9 sparked the gene editing revolution for both research and therapeutics.1 But this system still showed severe issues that limited its applications. The most prominent were the heavy reliance on PAM sequences, delivery limitations, double-stranded breaks that prompt unintended edits and cell death, and editing inefficiency (both in targeting and in knock-in reliability).

              Despite this, “CRISPR helped turn genome editing from a specialized technique into
              ...
              07-31-2026, 11:01 AM
            • SEQadmin2
              Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
              by SEQadmin2


              Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

              The systematic characterization of the human proteome has
              ...
              07-20-2026, 11:48 AM
            • SEQadmin2
              Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
              by SEQadmin2



              Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
              ...
              07-09-2026, 11:10 AM

            ad_right_rmr

            Collapse

            News

            Collapse

            Topics Statistics Last Post
            Started by SEQadmin2, Today, 10:13 AM
            0 responses
            13 views
            0 reactions
            Last Post SEQadmin2  
            Started by SEQadmin2, 07-31-2026, 02:55 AM
            0 responses
            23 views
            0 reactions
            Last Post SEQadmin2  
            Started by SEQadmin2, 07-24-2026, 12:17 PM
            0 responses
            19 views
            0 reactions
            Last Post SEQadmin2  
            Started by SEQadmin2, 07-23-2026, 11:41 AM
            0 responses
            18 views
            0 reactions
            Last Post SEQadmin2  
            Working...